Table 5.
Cox regression analysis of PCSK9, NFS and the combination of NFS and PCSK9 with events in male and female
| Variables | Male | Female | ||||
|---|---|---|---|---|---|---|
| Multivariable model | Multivariable model | |||||
| Events/ Subjects |
OR(95%CI) | P | Events/ Subjects |
OR(95%CI) | P | |
| NFS per 1-SD increase | 101/1215 | 1.528 (1.147,2.035) | 0.004 | 57/793 | 1.033 (0.739,1.446) | 0.848 |
| PCSK9 per 1-SD increase | 101/1215 | 1.344 (1.102,1.64) | 0.004 | 57/793 | 1.042 (0.81,1.341) | 0.747 |
| PCSK9 + NFS | ||||||
| Low PCSK9 + low NFS | 7/210 | 1.0 | 2/87 | 1.0 | ||
| Low PCSK9 + intermediate-high NFS | 20/265 | 1.907 (0.774,4.696) | 0.161 | 8/107 | 2.32 (0.465,11.588) | 0.310 |
| Intermediate PCSK9 + low NFS | 10/162 | 1.729 (0.65,4.603) | 0.273 | 5/96 | 2.216 (0.419,11.721) | 0.350 |
| Intermediate PCSK9 + intermediate-high NFS | 26/253 | 2.382 (0.985,5.764) | 0.054 | 13/159 | 2.511 (0.524,12.024) | 0.250 |
| High PCSK9 + low NFS | 11/134 | 2.236 (0.855,5.846) | 0.101 | 10/109 | 3.361 (0.708,15.95) | 0.130 |
| High PCSK9 + intermediate-high NFS | 27/191 | 3.377 (1.394,8.179) | 0.007 | 19/235 | 2.178 (0.468,10.131) | 0.320 |
PCSK9 proprotein convertase subtilisin/ kexin type 9, NFS non-alcoholic fatty liver disease fibrosis score, MACEs major adverse cardiovascular events, HR hazard ratio, CI confidence interval. Multivariable model was adjusted for body mass index, hypertension, family history of coronary artery disease, coronary artery disease, diabetes, smoking, drinking, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, hemoglobin A1c, antiplatelet drugs, antihypertensive drugs. P < 0.05 suggests significant difference